calithera
biosciences
announces
expansion
ongoing
clinical
trial
evaluating
telaglenastat
combination
palbociclib
south
san
francisco
globe
newswire
calithera
biosciences
nasdaq
cala
biotechnology
company
focused
discovering
developing
novel
drugs
treatment
cancer
diseases
today
announced
expansion
company
ongoing
clinical
trial
evaluating
telaglenastat
combination
pfizer
cdk
inhibitor
palbociclib
phase
study
conducted
calithera
expanded
include
additional
cohort
patients
pancreatic
ductal
adenocarcinoma
pdac
whose
tumors
harbor
mutations
kras
strong
rationale
target
kras
mutated
tumors
combination
palbociclib
telaglenastat
said
susan
molineaux
phd
president
chief
executive
officer
calithera
mutations
lead
upregulation
activity
glutamine
utilization
cancer
cells
inhibiting
activities
simultaneously
combination
hope
measurable
impact
pancreatic
cancer
still
viable
treatment
telaglenastat
blocks
glutamine
consumption
tumor
cells
due
specific
genetic
alterations
mutations
kras
often
become
dependent
increased
metabolism
glutamine
approximately
percent
pdac
patients
harbor
mutations
kras
preclinical
studies
cancer
models
telaglenastat
showed
synergistic
effects
used
combination
inhibitors
palbociclib
enhancing
cell
cycle
arrest
blocking
cancer
cell
proliferation
ongoing
phase
clinical
trial
encouraging
efficacy
safety
combination
observed
pdac
patients
treated
dose
escalation
phase
trial
new
cohort
phase
clinical
trial
evaluating
safety
activity
telaglenastat
combination
palbociclib
patients
advanced
metastatic
pdac
whose
tumors
harbor
mutations
kras
ongoing
phase
trial
currently
enrolling
patients
colorectal
cancer
cell
lung
cancer
whose
tumors
harbor
mutations
kras
calithera
calithera
biosciences
biopharmaceutical
company
pioneering
discovery
development
targeted
therapies
disrupt
cellular
metabolic
pathways
preferentially
block
tumor
cells
enhance
activity
driven
commitment
rigorous
science
passion
improving
lives
people
impacted
cancer
diseases
calithera
advancing
pipeline
oral
therapeutics
meaningfully
expand
treatment
options
available
patients
calithera
headquartered
south
san
francisco
california
information
calithera
please
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
anticipate
estimate
intend
poised
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
include
related
success
calithera
clinical
trial
potential
telaglenastat
developed
combination
therapeutics
palbociclib
improve
patient
outcomes
safety
tolerability
efficacy
telaglenastat
overall
advancement
telaglenastat
clinical
trials
unmet
need
treatment
patients
advanced
disease
calithera
plans
continue
development
telaglenastat
combination
cdk
inhibitor
palbociclib
treatment
crc
nsclc
pdac
well
related
timing
clinical
trials
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
product
candidates
calithera
develops
may
progress
clinical
development
receive
required
regulatory
approvals
within
expected
timelines
addition
clinical
trials
may
confirm
safety
potency
product
characteristics
described
assumed
press
release
product
candidates
may
beneficial
patients
successfully
commercialized
failure
meet
expectations
respect
foregoing
matters
may
negative
effect
calithera
stock
price
additional
information
concerning
risk
factors
affecting
calithera
business
found
calithera
recent
annual
report
form
filed
securities
exchange
commission
periodic
filings
securities
exchange
commission
statements
guarantees
future
performance
speak
date
hereof
except
required
law
calithera
disclaims
obligation
update
statements
reflect
future
events
circumstances
source
calithera
biosciences
incorporated
contacts
investor
relations
jennifer
mcnealey
calithera
ir
media
michele
parisi
sam
brown
micheleparisi
